Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Vicore Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2026 was $9.27 Mil. Vicore Pharma Holding AB's Total Assets for the quarter that ended in Mar. 2026 was $115.62 Mil.
Therefore, Vicore Pharma Holding AB's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.08.
Vicore Pharma Holding AB (NAS:VCRE) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Vicore Pharma Holding AB Liabilities-to-Assets Related Terms
Vicore Pharma Holding AB Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Vicore Pharma Holding AB's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB Liabilities-to-Assets Chart
For the Biotechnology subindustry, Vicore Pharma Holding AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's Liabilities-to-Assets falls into.
Vicore Pharma Holding AB Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Vicore Pharma Holding AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (VCRE) has a Liabilities-to-Assets of 0.08 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Liabilities-to-Assets too high?
Vicore Pharma Holding AB's current Liabilities-to-Assets is 0.08. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Liabilities-to-Assets compare to ?
Vicore Pharma Holding AB's Liabilities-to-Assets of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Liabilities-to-Assets is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current Liabilities-to-Assets of 0.08. The current Liabilities-to-Assets is 0.08. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current Liabilities-to-Assets is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score
Get the complete analysis for VCRE
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCRE has been successfully added to your 
